Corporate News

Pentracor GmbH publishes 2020 financial statements and makes good progress in the first half of 2021

Hennigsdorf, July 28, 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin has published its 2020 annual financial statements. The financial year was characterized by the roll-out of the PentraSorb® CRP medical product developed and certified by the company, as well as the initiation and execution of clinical studies to increase acceptance for CRP apheresis in the treatment of diseases associated with acute inflammation such as myocardial infarction.

Broad media coverage of Pentracor's promising blood wash therapy for COVID-19 patients

Hennigsdorf, 18.05.2021 - Today, the German TV station ZDF reported in detail about the promising CRP apheresis for COVID-19 patients from the medical technology company Pentracor GmbH based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB). At Berlin's Havelhöhe Community Hospital, Pentracor's new therapeutic extracorporeal treatment method is now being used with great success on many severely ill COVID-19 patients.

Promising treatment success in patients with severe COVID-19 courses

Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.

Tailwind for Pentracor's CRP blood wash as therapy

Hennigsdorf, February 17, 2021 - Pentracor GmbH, based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), has achieved a major success with the publication of an article in the renowned immunology journal "Frontiers in Immunology". The title: "C-reactive protein activates cell death in poorly perfused cell tissue". The article, reviewed by the editors and several physicians at Frontiers, can be considered a milestone in the formation of opinion for clinical physicians on the new view of the physiological function of the protein CRP.

World's only CRP blood wash therapy now also successful for COVID-19

Hennigsdorf, January 27, 2021 - The medical technology company Pentracor GmbH, headquartered in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has successfully treated a patient suffering from COVID-19 caused by the Corona virus with its CE-certified and patent-protected medical product PentraSorb® CRP. The company has thus created another important option for action in the fight against the often fatal effects of the pandemic.

Success for Pentracor at the German Medical Award 2020

Hennigsdorf, 20.11.2020 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved indirect success with its medical product PentraSorb® CRP. At the German Medical Award 2020, Prof. Dr. Jan Torzewski, head physician of the Heart and Vascular Center of the Allgäu Hospital Association at Kempten Hospital and a specialist in cardiology and intensive care medicine, secured 2nd place among 34 renowned participants.

Pentracor GmbH: Bond 2020/2025 successfully placed

Hennigsdorf, June 8, 2020 - The medical technology company Pentracor GmbH, operating in the dynamically growing healthcare sector, has almost completed the placement of its corporate bond with a possible conversion right (ISIN: DE000A289XB9, WKN: A289XB) via private placement with an issue volume of EUR 15 million. Final discussions with potential investors are still ongoing.

Medical technology company Pentracor GmbH issues corporate bond

Hennigsdorf, May 20, 2020 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin and operating in the dynamically growing healthcare sector, is issuing a bond with a possible conversion right (ISIN: DE000A289XB9, WKN: A289XB) via private placement. The issue volume is up to EUR 15 million, the interest rate is fixed at 8.50% p.a., the term of the bond is 5 years.

Ad hoc News

Publication of inside information in accordance with Article 17 MAR

 

Currently no notices published in this section.

Directors Dealings

Notification and public disclosure of the business of persons performing managerial responsibilities and persons closely related to them in accordance with Article 19 MAR

 

Currently no notices published in this section.

Contact

IR.on AG
Telephone: +49 221 9140 970
E-Mail: pentracor@ir-on.com

Subscribe to IR and Ad-hoc News now

Über unseren Verteiler erhalten Sie aktuelle Unternehmens- und Finanzmitteilungen der Pentracor GmbH.

*Ich möchte per E-Mail Unternehmens- und Finanzmitteilungen zur Pentracor GmbH erhalten. Diese Einwilligung zur Nutzung meiner E-Mail-Adresse kann ich jederzeit für die Zukunft widerrufen. Die Verwendung personenbezogener Daten sowie weitere Informationen zum Datenschutz finden Sie in unserer Datenschutzerklärung.